ArticleBJU international2016
Causes of death in men with localized prostate cancer: a nationwide, population-based study.
Article in BJU international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes.Prostate cancer and prostatic diseases · 2022Pooled it
- Racial disparity in microvascular function among non-Hispanic white and non-Hispanic black men with newly diagnosed prostate cancer.Physiological reports · 2026Article
- Advanced risk signature analysis of inflammation markers in predicting prostate cancer using the Swedish Apolipoprotein-related MOrtality RISk (AMORIS) cohort.ESMO real world data and digital oncology · 2025Article
- Mortality Risks Associated with Depression in Men with Prostate Cancer.European urology oncology · 2024Article
- Article
- Article
- Cardiovascular mortality by cancer risk stratification in patients with localized prostate cancer: a SEER-based study.Frontiers in cardiovascular medicine · 2023Article
- Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study.Nutrition and cancer · 2023Article
- Article
- Causes of Death after Prostate Cancer Diagnosis: A Population-Based Study.Oxidative medicine and cellular longevity · 2022Article
- ZNF507 affects TGF-β signaling via TGFBR1 and MAP3K8 activation in the progression of prostate cancer to an aggressive state.Journal of experimental & clinical cancer research : CR · 2021Article
- Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016.JAMA network open · 2021Article
- Article
- All-Cause Mortality Risk in National Prostate Cancer Cohort: An Impact of Population-Based Prostate Cancer Screening.Journal of clinical medicine · 2021Article
- Article
- Adherence to Mediterranean Diet, Physical Activity and Survival after Prostate Cancer Diagnosis.Nutrients · 2021Article
- A drug comorbidity index to predict mortality in men with castration resistant prostate cancer.PloS one · 2021Article
- Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study.BMC cancer · 2020Article
- The burden of chronic diseases among Australian cancer patients: Evidence from a longitudinal exploration, 2007-2017.PloS one · 2020Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo detail the distribution of causes of death from localized prostate cancer (PCa). PATIENTS AND
methodsThe database PCBase Sweden links the Swedish National Prostate Cancer Register with other nationwide population-based healthcare registers. We selected all 57 187 men diagnosed with localized PCa between 1997 and 2009 and their 114 374 PCa-free control subjects, matched according to age and county of residence. Mortality was calculated using competing risk regression analyses, taking into account PCa risk category, age and Charlson comorbidity index (CCI).
resultsIn men with low-risk PCa, all-cause mortality was lower compared with that in corresponding PCa-free men: 10-year all-cause mortality was 18% for men diagnosed at age 70 years, with a CCI score of 0, and 21% among corresponding control subjects. Of these cases, 31% died from cardiovascular disease (CVD) compared with 37% of the corresponding control subjects. For men with low-risk PCa, 10-year PCa-mortality was 0.4, 1 and 3% when diagnosed at age 50, 60 and 70 years, respectively. PCa was the third most common cause of death (18%), after CVD (31%) and other cancers (30%). By contrast, PCa was the most common cause of death in men with intermediate- and high-risk localized PCa.
conclusionsMen with low-risk PCa had lower all-cause mortality than PCa-free men because of lower CVD mortality, driven by early detection selection; however, for men with intermediate- or high-risk disease, the rate of PCa death was substantial, irrespective of CCI score, and this was even more pronounced for those diagnosed at age 50 or 60 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.